{"id":{"repo_id":"usfca","oai_identifier":"oai:repository.usfca.edu:capstone-2739"},"canonical_url":"https://search.ndltd.org/etd/usfca/oai:repository.usfca.edu:capstone-2739","repository":{"repo_id":"usfca","name":"University of San Francisco","base_url":"https://repository.usfca.edu/do/oai/"},"display":{"title":"Tepezza: Improving Delays in Treatment","abstract":"Problem: There is gap in time from when a Tepezza (teprotumumab) order is placed until the time a patient receives their first infusion. Context: Delays in the initiation of Tepezza infusions result in worsening symptoms and a decrease in quality of life for patients diagnosed with thyroid eye disease. Interventions: Interventions included scheduling regular meetings with involved departments, following each patient who has been prescribed Tepezza through the initiation of therapy, and improving staff and patient education. Measures: Outcome measures include decreasing days from order placement to first infusion from an average of 61 days to 30 days or less and increasing patient education and satisfaction. Process measures consist of establishing regular meetings with stakeholders, following patients from order to first infusion to collect data, creating a patient education pamphlet, and initiating a patient satisfaction survey. Balancing measures include maintaining regular meetings with stakeholders to assure that other involved departments do not sustain additional burden with new clinic workflows. Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30 days from the time the order was initiated. Conclusions: A timely benefits investigation, in addition to improved communication amongst stakeholders, led to the improvement in the previous delays in care.","abstract_html":"Problem: There is gap in time from when a Tepezza (teprotumumab) order is placed until the time a patient receives their first infusion. Context: Delays in the initiation of Tepezza infusions result in worsening symptoms and a decrease in quality of life for patients diagnosed with thyroid eye disease. Interventions: Interventions included scheduling regular meetings with involved departments, following each patient who has been prescribed Tepezza through the initiation of therapy, and improving staff and patient education. Measures: Outcome measures include decreasing days from order placement to first infusion from an average of 61 days to 30 days or less and increasing patient education and satisfaction. Process measures consist of establishing regular meetings with stakeholders, following patients from order to first infusion to collect data, creating a patient education pamphlet, and initiating a patient satisfaction survey. Balancing measures include maintaining regular meetings with stakeholders to assure that other involved departments do not sustain additional burden with new clinic workflows. Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30 days from the time the order was initiated. Conclusions: A timely benefits investigation, in addition to improved communication amongst stakeholders, led to the improvement in the previous delays in care.","abstract_has_math":false,"creators":["Page, Rebecca D"],"institution":null,"degree_name":"Master of Science in Nursing (MSN)","degree_level":"Project/Capstone - Global access","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Dr. Susan Mortell"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:37:54Z","subjects":["Thyroid eye disease","TED","Tepezza","teprotumumab","Graves’ disease","prior authorization","Other Nursing"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://repository.usfca.edu/capstone/1398","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://repository.usfca.edu/capstone/1398","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://repository.usfca.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Arepository.usfca.edu%3Acapstone-2739","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Susan Mortell"]},{"key":"dc:creator","label":"Author","values":["Page, Rebecca D"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-08-11T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2022-08-12T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Project/Capstone - Global access"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science in Nursing (MSN)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Thyroid eye disease","TED","Tepezza","teprotumumab","Graves’ disease","prior authorization","Other Nursing"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://repository.usfca.edu/capstone/1398"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Problem: There is gap in time from when a Tepezza (teprotumumab) order is placed until the time a patient receives their first infusion. Context: Delays in the initiation of Tepezza infusions result in worsening symptoms and a decrease in quality of life for patients diagnosed with thyroid eye disease. Interventions: Interventions included scheduling regular meetings with involved departments, following each patient who has been prescribed Tepezza through the initiation of therapy, and improving staff and patient education. Measures: Outcome measures include decreasing days from order placement to first infusion from an average of 61 days to 30 days or less and increasing patient education and satisfaction. Process measures consist of establishing regular meetings with stakeholders, following patients from order to first infusion to collect data, creating a patient education pamphlet, and initiating a patient satisfaction survey. Balancing measures include maintaining regular meetings with stakeholders to assure that other involved departments do not sustain additional burden with new clinic workflows. Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30 days from the time the order was initiated. Conclusions: A timely benefits investigation, in addition to improved communication amongst stakeholders, led to the improvement in the previous delays in care."]},{"key":"dc:title","label":"Title","values":["Tepezza: Improving Delays in Treatment"]}]}],"canonical_facts":{"dc:contributor":["Dr. Susan Mortell"],"dc:creator":["Page, Rebecca D"],"dc:date.available":["2022-08-11T07:00:00Z"],"dc:date.created":["2022-08-12T07:00:00Z"],"dc:description.abstract":["Problem: There is gap in time from when a Tepezza (teprotumumab) order is placed until the time a patient receives their first infusion. Context: Delays in the initiation of Tepezza infusions result in worsening symptoms and a decrease in quality of life for patients diagnosed with thyroid eye disease. Interventions: Interventions included scheduling regular meetings with involved departments, following each patient who has been prescribed Tepezza through the initiation of therapy, and improving staff and patient education. Measures: Outcome measures include decreasing days from order placement to first infusion from an average of 61 days to 30 days or less and increasing patient education and satisfaction. Process measures consist of establishing regular meetings with stakeholders, following patients from order to first infusion to collect data, creating a patient education pamphlet, and initiating a patient satisfaction survey. Balancing measures include maintaining regular meetings with stakeholders to assure that other involved departments do not sustain additional burden with new clinic workflows. Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30 days from the time the order was initiated. Conclusions: A timely benefits investigation, in addition to improved communication amongst stakeholders, led to the improvement in the previous delays in care."],"dc:identifier":["https://repository.usfca.edu/capstone/1398"],"dc:subject":["Thyroid eye disease","TED","Tepezza","teprotumumab","Graves’ disease","prior authorization","Other Nursing"],"dc:title":["Tepezza: Improving Delays in Treatment"],"thesis:degree_level":["Project/Capstone - Global access"],"thesis:degree_name":["Master of Science in Nursing (MSN)"]},"updated_at":"2026-11-19T08:37:54Z"}